The problem
Most heart disease goes undiagnosed because clinicians can't reliably hear murmurs or weak hearts with an analog stethoscope
What they do
AI-powered digital stethoscopes that flag heart murmurs, low EF and AFib during routine exams
Traction 750,000 stethoscopes sold (up from 650,000 in Jul 2025); 9 FDA clearances; CMS payment for SENSORA
Hiring trend
- Open roles
- 9
- Headcount
- ~200
Flat, ~201 staff (+0.4% YoY, down 18.5% from 2023 peak of 247); postings up 113% in 2026 (Revelio)
Hiring in
- Emeryville
- Remote (US)
Glassdoor
4.2 ★ 37 reviews ↗Funding
- Last round
- $41M
- Stage
- Series D
- Date
- Jun 2024
Led by ARTIS Ventures, Highland Capital Partners, NTTVC, Questa Capital (participants; no lead named)
- Hiring+19 open roles on the live job board (3–9 roles = +1)
- Funding recency0Series D · $41M, Jun 2024 (28 months ago): over 24 months = 0
- Traction+0.75Some growth: 750,000 stethoscopes sold (up from 650,000 in Jul 2025); 9 FDA clearances; CMS payment for SENSORA
- Red flags0Watch-outs noted below, none scored as a significant flag
- Total1.751 + 0 + 0.75 − 0 = 1.75 → Steady (1.5–3.49)
Distance (Half) is a separate read on how long the lead can last. It doesn't change the score.
Distance
Half · edge: learns from use
The category leader in AI digital stethoscopes: 750,000 devices sold, 9 FDA clearances, a foundation model trained on 4M+ heart recordings, and CMS reimbursement are hard for anyone to copy. Still small for medtech, with no new funding since 2024 and its own store's sales slipping.
Sources: Eko: 750,000 devices sold, 9 FDA clearances (May 2026) ↗ · TechTarget: Wayne General deploys SENSORA; EFAST model cleared Sep 2025, CMS rate $128.90 (Apr 2026) ↗ · TechCrunch: Eko Health $41M Series D, $165M total (Jun 2024) ↗
Watch-outs
Watch-outs (no -1 applied): no priced round in 28 months, and the Jun 2024 Series D was a down round (~$271M vs ~$395M in 2022, secondary-market estimate). Headcount fell 18.5% from its 2023 peak and has been flat since. A Jul 2026 Glassdoor review cites 'massive layoffs every 2 years', though no layoff was reported in the press in the last 24 months.
Sources: StockAnalysis/Forge: Eko Health valuation history, Series D -31% (Oct 2026) ↗ · Revelio Labs: Eko Health headcount 247 (2023) to 201 (2026) ↗ · Glassdoor: Eko reviews, incl. Jul 2026 'frequent layoffs' review ↗
Open ops roles
No ops roles open right now
Last checked Oct 25, 2026